Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception

Dubinett, Steven M.; Spira, Avrum

doi:10.1164/rccm.201710-2065ed

Cited by 5 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is associated with abnormal inflammatory reactions of harmful gases and harmful particles and has high morbidity and mortality. More and more studies have found that the COPD that is a chronic inflammatory pulmonary disease is an important risk factor of lung cancer [16, 28–32]. COPD-induced hypoxia in the lungs activates hypoxic transcription factors that inhibit apoptosis, which might trigger lung cancer [33].…”

Section: Chronic Inflammation In Different Types Of Cancersmentioning

confidence: 99%

Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles

2019

View full text Add to dashboard Cite

A strong relationship exists between tumor and inflammation, which is the hot point in cancer research. Inflammation can promote the occurrence and development of cancer by promoting blood vessel growth, cancer cell proliferation, and tumor invasiveness, negatively regulating immune response, and changing the efficacy of certain anti-tumor drugs. It has been demonstrated that there are a large number of inflammatory factors and inflammatory cells in the tumor microenvironment, and tumor-promoting immunity and anti-tumor immunity exist simultaneously in the tumor microenvironment. The typical relationship between chronic inflammation and tumor has been presented by the relationships between Helicobacter pylori, chronic gastritis, and gastric cancer; between smoking, development of chronic pneumonia, and lung cancer; and between hepatitis virus (mainly hepatitis virus B and C), development of chronic hepatitis, and liver cancer. The prevention of chronic inflammation is a factor that can prevent cancer, so it effectively inhibits or blocks the occurrence, development, and progression of the chronic inflammation process playing important roles in the prevention of cancer. Monitoring of the causes and inflammatory factors in chronic inflammation processes is a useful way to predict cancer and assess the efficiency of cancer prevention. Chronic inflammation-based biomarkers are useful tools to predict and prevent cancer.

show abstract

Section: Chronic Inflammation In Different Types Of Cancersmentioning

confidence: 99%

Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles

2019

View full text Add to dashboard Cite

show abstract

“…Mark and colleagues noted that lungs of patients with COPD had greater numbers of CD3 1 , CD4 1 , and CD8 1 cells as well as increased CD4 1 Th1 polarization compared with lungs of smokers without COPD (29). This finding was present both in the noncancerous lung tissue as well as in the matching cancer, suggesting that the immune composition of the lung permeates the tumor environment (29,30). Further research is needed to clarify whether the Th1 differentiation in COPD-affected lung tissue is responsible for the observed improved outcomes after immunotherapy.…”

Section: Lung Cancer and Immunotherapymentioning

confidence: 99%

Update in Chronic Obstructive Pulmonary Disease 2018

Labaki

Kimmig

Mutlu

et al. 2019

Am J Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…In medical research, the term ‘disease interception’ is relatively young and just beginning to gain more momentum—especially in cancer and neurodegenerative research. A Medline search results in only eight publications that use the term in the title—three of them with authors from one pharmaceutical company ( Blackburn, 2011 ; Hait and Lebowitz, 2016 ; Beane et al , 2017 ; Khan et al , 2017 ; Walsh et al , 2017 ; Dubinett and Spira, 2018 ; Albini et al , 2019 ; Kampylafka et al , 2019 ). Recently, the company has initiated the publication of the first volume of essays on the subject ( Jessen and Bug, 2019 ) and even proclaimed a ‘paradigm shift’ in medicine ( Klosterkötter, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

“…In these works and especially in the pharmaceutical public relations documents, the intriguing term ‘disease interception’ is used for reporting new treatment strategies for chronic diseases such as cancer and degenerative diseases. In these, there appears to be a therapeutic window at an early stage where treatment can prevent the irreparable consequences of the disease: the genesis of cancer ( Blackburn, 2011 ; Beane et al , 2017 ; Dubinett and Spira, 2018 ; Albini et al , 2019 ), the destruction of nerve cells (Alzheimer’s dementia) ( Walsh et al , 2017 ; Albini et al , 2019 ), the destruction of joints (rheumatoid arthritis) ( Raza and Filer, 2015 ; Cossu et al , 2017 ; Cole et al , 2018 ) or the loss of islet beta-cell function (diabetes) ( Insel et al , 2017 ; Merino et al , 2018 ). For these cases, the picture of ‘interception’ seems fitting, as in the case of the player, who intercepts the ball and thus interrupts the determined and predictable trajectory of its flight.…”

Section: Introductionmentioning

confidence: 99%

Nipping Diseases in the Bud? Ethical and Social Considerations of the Concept of ‘Disease Interception’

Narchi

Winkler

2021

Public Health Ethics

View full text Add to dashboard Cite

‘Disease interception’ describes the treatment of a disease in its clinically inapparent phase and is increasingly used in medical literature. However, no precise definition, much less an ethical evaluation, has been developed yet. This article starts with a definition of ‘disease interception’ by distinguishing it from other preventions. It then analyses the ethical and social implications of the concept in light of the four principles of medical ethics by Beauchamp and Childress. The term ‘disease interception’ refers to a form of secondary prevention applied in a short interception window intended to prevent a preclinical disease from developing further. We propose the definition ‘early and targeted secondary prevention by treatment’. The ethical evaluation of the concept shows that while it promises to be beneficial, it raises a number of ethical and social challenges regarding patient autonomy and justice. In order to ensure decision-making that respects patient autonomy, commercially motivated metaphors such as ‘disease interception’ should make way for precise definitions. Future research should not only focus on how to detect clinically inapparent diseases but also on the ethical question, when this is justifiable and what consequences it has for the individual and society as a whole.

show abstract

Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception

Cited by 5 publications

References 17 publications

Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles

Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles

Update in Chronic Obstructive Pulmonary Disease 2018

Nipping Diseases in the Bud? Ethical and Social Considerations of the Concept of ‘Disease Interception’

Contact Info

Product

Resources

About